Ocular Therapeutix (OCUL) Reports Q2 Loss, Tops Revenue Estimates

This article was originally published on Nasdaq

Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.28 per share a year ago. These figures are adjusted for non-recurring